TNG:EPA
Transgene SA
€0.68
arrow_downward
-0.73%(-0.0050) 1D
Oct 19, 5:35:04 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
€0.69
High
€0.70
Low
€0.68
Mkt. cap
191.94M
Avg. vol.
111.65K
Volume
53.57K
52-wk high
€1.50
52-wk low
€0.68
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
Open
€0.69
High
€0.70
Low
€0.68
Mkt. cap
191.94M
Avg. vol.
111.65K
Volume
53.57K
52-wk high
€1.50
52-wk low
€0.68
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
News stories
From web sources and news partners
BigGo Finance
·
38 minutes ago
Chip Stocks Rebound; Nasdaq Gains 1.1%, Dow Slips 36 Points
RealMoney Pro
·
1 hour ago
Tech Bounces Back but Rising Yields Pressure Non-Tech
BigGo Finance
·
1 hour ago
Dow Falls 36 Points for Second Straight Session as Oil Rally Weighs, AI-Related Buying Provides Support
Investing.com
·
3 hours ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA